Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane)

Trial Profile

Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms ETNA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2017 Planned End Date changed from 1 Oct 2025 to 31 Dec 2025.
    • 07 Jul 2016 This trial was prematurely ended in Austria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top